Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omacor
- Development stage
- Phase 1
- Lead developer
- BASF
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omacor is a prescription-grade concentrate of omega-3 polyunsaturated fatty acids (n-3 PUFA), primarily consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters. It is being evaluated in the Phase 3 PUFFIN trial, sponsored by the Norfolk and Norwich University Hospitals NHS Foundation Trust, for its efficacy in improving asthma control in patients with aspirin-exacerbated respiratory disease (N-ERD), also known as non-steroidal exacerbated airways disease. The mechanism involves the modulation of the arachidonic acid pathway, specifically reducing the production of pro-inflammatory 4-series leukotrienes and increasing the production of less inflammatory 5-series leukotrienes and specialized pro-resolving mediators. By competing with arachidonic acid for metabolic enzymes, Omacor helps resolve chronic airway inflammation characteristic of N-ERD.
- Brand names
- OmacorLovaza
- Other names
- omega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl estersn-3 polyunsaturated fatty acidsn3 polyunsaturated fatty acidsn 3 polyunsaturated fatty acidsn-3 PUFAn3 PUFAn 3 PUFAfish oil
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)ALOX5 (Arachidonate 5-lipoxygenase)
Beyond the preview
Go deeper on Omacor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omacor.